Spray dried human plasma

ABSTRACT

The technology relates to spray dried plasma and methods of making the same. The method includes providing plasma to a spray drying apparatus, spray drying the plasma, at the spray drying apparatus, to form physiologically active plasma powder, the spray drying apparatus configured utilizing one or more parameters, and storing the physiologically active plasma powder.

CROSS REFERENCE TO RELATED APPLICATION

This application is a continuation of U.S. patent application Ser. No.13/556,834, filed on Jul. 24, 2012, which is a continuation applicationof U.S. patent application Ser. No. 12/884,052, filed on Sep. 16, 2010which claims priority to U.S. Provisional Patent Application No.61/243,034, filed Sep. 16, 2009, the entire contents of which areincorporated in their entirety herein by reference.

FIELD OF THE INVENTION

The present invention relates generally to methods and apparatus forproducing and/or using spray dried human plasma.

BACKGROUND

Blood plasma is the yellow liquid component of blood, in which the bloodcells of whole blood would normally be suspended. Blood plasma makes upabout 55% of the total blood volume. Blood plasma is mostly water (e.g.,90% by volume) and contains dissolved proteins, glucose, clottingfactors, mineral ions, hormones, and/or carbon dioxide. Blood plasma isprepared by spinning a tube of fresh blood in a centrifuge until theblood cells fall to the bottom of the tube. The blood plasma is thenpoured or drawn off. Blood plasma is frequently frozen fresh for futureuses. Although frozen plasma is the current standard of care, there arenumerous problems with this technology. For example, the bag containingthe frozen plasma become brittle and often gets damaged during storageor transportation. Maintaining frozen plasma at the appropriatetemperature during storage and transportation is very expensive. Itrequires mechanical freezers to keep the frozen plasma at −18° C. orlower. Shipping requires special shipping containers to maintain thefrozen state and reduce breakage of the bag. Use of the frozen plasma isdelayed by 30-45 minutes due to the thawing time. Moreover, thepreparation for use requires trained staff and specialized thawingdevice in a regulated laboratory. Finally, fresh frozen plasma has alimited shelf life of 12 months at −18° C. Once thawed, the frozenplasma must be used within 24 hours.

In an attempt to avoid the disadvantages of frozen plasma, some havefreeze dried (i.e., lyophilized) plasma. However, the freeze dryingprocess produces a product composed of large, irregular sized grains orparticles. Such products can be difficult or impossible to reconstituteto a form suitable for administration to a patient. Furthermore, thefreeze drying process requires transfer of the product from thelyophilizer to the final container, thus requiring post-processingsterility testing. The freeze drying process can only be done in batchmode; continuous processing is not possible with freeze drying.Moreover, manufacturing scale-up requires changes to the freeze dryingprocess, and there are protein recovery issues at scale-up.

Accordingly, a need still exists in the field for plasma that may bestored in a wide range of environments without freezers orrefrigerators, be available for use by first responders at the initialpoint of care, and can be transfused in minutes without the 30-45 minutedelay associated with thawing of frozen plasma.

SUMMARY OF THE INVENTION

The present invention provides an extracorporeal sterile, closed plasmaprocessing system, which can be used to produce a spray dried,physiologically active plasma powder product that has a long storagelife at room temperature; that can easily be stored and shipped; that isversatile, durable and simple, and that can be easily and rapidlyreconstituted and used at the point of care. The processing system ofthe present invention can produce spray dried plasma in either a batch(single unit) or a continuous (pooled units) process mode. The resultingplasma powder can be dried directly into the final, attached sterilecontainer, which can later be rapidly and easily reconstituted toproduce transfusion grade plasma. The spray dried powder can be storedat least 2-3 years at virtually any temperature (e.g., −180° C. to 50°C.). The costs associated with storage and shipping of the spray driedpowder are significantly lower, because of its lighter weight andbroader range of temperature tolerance compared to frozen plasma. At thepoint of care, the spray dried powder is rapidly reconstituted (30-120seconds), avoiding the need for special equipment and trained staff. Incontrast to frozen plasma, which takes 30-45 minutes to thaw and must beused within 24 hours, the spray dried plasma of the present inventionavoids waste since the caregiver can rapidly prepares the amount ofplasma required for a given patient, rather than trying to assess andpredict the amount of plasma required and thawing sufficient plasma tomeet this anticipated need.

One approach to spray dried human plasma is a method that includesproviding plasma to a spray drying apparatus; spray drying the plasma,at the spray drying apparatus, to form physiologically active plasmapowder, the spray drying apparatus configured utilizing one or moreparameters; and storing the physiologically active plasma powder.

Another approach to spray dried human plasma is a spray dryingapparatus. The spray drying apparatus includes a pump device configuredto transport plasma from a liquid plasma storage device at a pump rate;a heated air stream device configured to deliver an air stream at aninlet temperature; a non reactive gas supply device configured to supplya non reactive gas at a flow rate; a spray nozzle configured to spraythe plasma into a spray chamber utilizing the non reactive gas and theair stream; and a particle collection device configured to collect thesprayed dried plasma via a vacuum formed by a vacuum pump at anaspiration setting.

Another approach to spray dried human plasma is a method. The methodincludes providing a physiologically active plasma powder; providing areconstitution fluid; and reconstituting physiologically activereconstituted plasma by mixing the physiologically active plasma powderand the reconstitution fluid.

Another approach to spray dried human plasma is a method. The methodincludes providing, from a non reactive gas supply to a spray nozzle, anon reactive gas at a flow rate; providing, from a dehumidifier to thespray nozzle, a heated air stream at an inlet temperature; providing,from a pump device to the spray nozzle, plasma at a pump setting;spraying, at the spray nozzle, the non reactive gas, the heated airstream, and the plasma into a spray chamber to form a physiologicallyactive plasma powder, the heated air stream enabling transfer ofmoisture from the plasma to the heated air stream.

Another approach to spray dried human plasma is a spray driedphysiologically active plasma powder. The spray dried physiologicallyactive plasma powder is prepared by providing plasma to a spray dryingapparatus; and spray drying, at the spray drying apparatus, the plasmato form the physiologically active plasma powder, the spray dryingapparatus configured utilizing one or more parameters.

Another approach to spray dried human plasma is a physiologically activereconstituted plasma. The physiologically active reconstituted plasma isprepared by providing plasma to a spray drying apparatus; spray drying,at the spray drying apparatus, the plasma to form physiologically activeplasma powder, the spray drying apparatus configured utilizing one ormore parameters; and reconstituting the physiologically active plasmapowder utilizing a reconstitution fluid to form the physiologicallyactive reconstituted plasma.

As mentioned above, the processing systems of the type described hereincan be used to produce spray dried physiologically active plasma powderin either a batch (single unit) or a continuous (pooled units) processmode.

One approach to spray dried human plasma is a method that starts withone unit of plasma and produces spray dried physiologically activeplasma powder from that same unit of plasma. One advantage of thisapproach is that it allows the coding of the plasma unit, which permitstracking and removal of a particular plasma unit from circulation if anissue (e.g., infection, contamination) is subsequently identified withthe original donor.

Another approach to spray dried human plasma is a method that startswith two or more single units of plasma and produces a pooled spraydried physiologically active plasma powder from these specific units ofplasma. In addition to the ability to track the resulting product,another advantage of this approach is that the pooled powder can bereconstituted in a smaller volume to produce a high potency plasma unit.For example, if two units of plasma are spray dried and laterreconstituted in one volume of reconstitution fluid, the resultingplasma would contain twice the concentration of physiologically activeproteins, clotting factors, etc.

Yet another approach to spray dried human plasma is a method that startswith a pooled source of plasma containing two or more pooled singleunits of plasma and produces a series of single units of spray driedphysiologically active plasma powder. This approach offers theefficiency advantages of a continuous processing mode to producenumerous single units of spray dried physiologically active plasmapowder.

Yet another approach to spray dried human plasma is a method that startswith a pooled source of plasma containing two or more pooled singleunits of plasma and produces a pooled amount of spray driedphysiologically active plasma powder. This approach offers theefficiency advantages of a continuous processing mode. This approachcould be used, for example, to produce larger amounts of spray driedphysiologically active plasma powder to be applied directly to an openwound.

In other embodiments, any of the approaches above can include one ormore of the following features.

In one aspect, a method is disclosed for spray drying plasma, the methodincluding: providing plasma to a spray drying apparatus; spray drying,at the spray drying apparatus, the plasma to form physiologically activeplasma powder; and storing the physiologically active plasma powder.

Some embodiments include, during the providing, spray drying, andstoring steps, maintaining the plasma and plasma powder in an isolatedsterile environment. Some embodiments include, processing plasma in aclosed sterile process to produce physiologically active plasma powdersuitable for reconstitution and transfusion to a human subject.

Some embodiments include, during the spray drying, maintaining theplasma at a temperature below a threshold temperature to preventdenaturing of proteins in the plasma. In some embodiments, the thresholdtemperature is 44° C. or less. In some embodiments, the thresholdtemperature is 48° C. or less. In some embodiments, the thresholdtemperature is 50° C. or less.

Some embodiments include, during the spray drying, maintaining theplasma at a temperature within a selected temperature range. Someembodiments include during the spray drying, maintaining the plasma at atemperature within a selected temperature range of 41-43° C. or 37-48°C.

In some embodiments, spray drying the plasma includes: directing plasmato a spray nozzle at a plasma flow rate; directing a heated drying gasto a drying chamber at an inlet temperature and a drying gas flow rate;directing a non reactive spray gas to the nozzle at a spray gas flowrate; combing the plasma and spray gas at the nozzle to atomize theplasma and dry the plasma; and combining the atomized plasma and dryinggas to dry the atomized plasma.

In some embodiments, the inlet temperature is in the range of 85-120° C.or 92-117° C.

In some embodiments, the plasma flow rate is in the range of 2-20mL/minute, 2-30 mL/min, 2-50 mL/min, etc. In some embodiments, thedrying gas flow rate is in the range of 20-80 m³/hour. In someembodiments, the spray gas flow rate is in the range of 300-500 L/hr.

In some embodiments, the plasma flow rate is in the range of 8-12mL/minute. In some embodiments, the drying gas flow rate is in the rangeof 30-40 m³/hour. In some embodiments, and the spray gas flow rate is inthe range of 350-450 L/hr.

Some embodiments include determining an outlet temperature of the plasmapowder; and adjusting at least one of: the plasma flow rate, the inlettemperature, the spray gas flow rate, and the drying gas flow rate basedon the outlet temperature.

Some embodiments include reconstituting the physiologically activeplasma powder utilizing a reconstitution fluid to form physiologicallyactive reconstituted plasma.

Some embodiments include applying the physiologically activereconstituted plasma to a human. In some embodiments, the reconstitutionfluid includes at least one selected from the list consisting of:distilled water, saline solution, and glycine. In some embodiments, thereconstitution fluid is a buffered solution.

In some embodiments, the powder, when reconstituted, exhibitsphysiological activity substantially equivalent to Thawed Plasma, LiquidPlasma, FP24, or FFP.

In some embodiments, the dried plasma, when reconstituted, ischaracterized by an aPTT of about 65 seconds or less, a PT of about 31seconds or less, and a Fibrinogen level of at least about 100 mg/dL.

In some embodiments, the dried plasma, when reconstituted, ischaracterized by an aPTT of about 35 seconds or less, a PT of about 15seconds or less, and a Fibrinogen level of at least about 223 mg/dL.

In some embodiments, the dried plasma, when reconstituted, ischaracterized by an aPTT in the range of 28-66 seconds, a PT in therange of 14-31 seconds, and a Fibrinogen level in the range of 100-300mg/dL.

In some embodiments, the dried plasma, when reconstituted, ischaracterized by an aPTT in the range of 30-35 seconds, a PT in therange of 10-15 seconds, and a Fibrinogen level in the range of 223-500mg/dL.

In some embodiments, the dried plasma, when reconstituted, ischaracterized by at least one of: a Factor VII level of at least about10 IU/dL, a Factor IX level of at least about 10 IU/dL, a Protein Clevel of at least about 10 IU/dL, and a Protein S level of at leastabout 10 IU/dL.

In some embodiments, the dried plasma, when reconstituted, ischaracterized by at least one of: a Factor VII level of at least about30 IU/dL, a Factor IX level of at least about 25 IU/dL, a Protein Clevel of at least about 55 IU/dL, and a Protein S level of at leastabout 54 IU/dL

In some embodiments, the dried plasma, when reconstituted, ischaracterized by at least one of: a Factor VII level of at least about54 IU/dL, a Factor IX level of at least about 70 IU/dL, a Protein Clevel of at least about 74 IU/dL, and a Protein S level of at leastabout 61 IU/dL.

In some embodiments, the dried plasma, when reconstituted, ischaracterized by at least one of: a Factor VII level in the range of30-110 IU/dL, a Factor IX level in the range of 25-135 IU/dL, a ProteinC level in the range of 55-130 IU/dL, and a Protein S level of in therange of 55-110 IU/dL.

In some embodiments, the dried plasma, when reconstituted, ischaracterized by at least one of: a Factor VII level in the range of34-172 IU/dL, a Factor IX level in the range of 70-141 IU/dL, a ProteinC level in the range of 74-154 IU/dL, and a Protein S level of in therange of 61-138 IU/dL.

In some embodiments, the dried plasma, when reconstituted, ischaracterized by at least one of: a Factor V level of at least about 10IU/dL, and a Factor VIII level of at least about 10 IU/dL.

In some embodiments, the dried plasma, when reconstituted, ischaracterized by at least one of: a Factor V level of at least about 30IU/dL, and a Factor VIII level of at least about 25 IU/dL.

In some embodiments, the dried plasma, when reconstituted, ischaracterized by at least one of: a Factor V level of at least about 63IU/dL, and a Factor VIII level of at least about 47 IU/dL.

In some embodiments, the dried plasma, when reconstituted, ischaracterized by at least one of a Factor V level in the range of 63-135IU/dL, a Factor VIII level in the range of 47-195 IU/dL.

In some embodiments, the powder has an average particle size of about 30microns or less. In some embodiments, e the powder has a maximumparticle size of about 100 microns or less.

In some embodiments, the powder includes at least 30% dried protein byweight.

In some embodiments, when reconstituted with 1 mL of fluid per 0.09grams of powder, the reconstituted plasma has a protein concentration inthe range of 35 mg/mL to 60 mg/mL.

In another aspect, a product is disclosed including: a physiologicallyactive dried plasma in the form of a powder. In some embodiments, thephysiologically active dried plasma is sterile.

In some embodiments, the powder, when reconstituted, exhibitsphysiological activity substantially equivalent to Thawed Plasma, LiquidPlasma, FP24, or FFP.

In some embodiments, the dried plasma, when reconstituted, ischaracterized by an aPTT of about 65 seconds or less, a PT of about 31seconds or less, and a Fibrinogen level of at least about 100 mg/dL.

In some embodiments, the dried plasma, when reconstituted, ischaracterized by an aPTT of about 35 seconds or less, a PT of about 15seconds or less, and a Fibrinogen level of at least about 223 mg/dL.

In some embodiments, the dried plasma, when reconstituted, ischaracterized by an aPTT in the range of 28-66 seconds, a PT in therange of 14-31 seconds, and a Fibrinogen level in the range of 100-300mg/dL.

In some embodiments, the dried plasma, when reconstituted, ischaracterized by an aPTT in the range of 30-35 seconds, a PT in therange of 10-15 seconds, and a Fibrinogen level in the range of 223-500mg/dL.

In some embodiments, the dried plasma, when reconstituted, ischaracterized by at least one of: a Factor VII level of at least about10 IU/dL, a Factor IX level of at least about 10 IU/dL, a Protein Clevel of at least about 10 IU/dL, and a Protein S level of at leastabout 10 IU/dL.

In some embodiments, the dried plasma, when reconstituted, ischaracterized by at least one of: a Factor VII level of at least about30 IU/dL, a Factor IX level of at least about 25 IU/dL, a Protein Clevel of at least about 55 IU/dL, and a Protein S level of at leastabout 54 IU/dL

In some embodiments, the dried plasma, when reconstituted, ischaracterized by at least one of: a Factor VII level of at least about54 IU/dL, a Factor IX level of at least about 70 IU/dL, a Protein Clevel of at least about 74 IU/dL, and a Protein S level of at leastabout 61 IU/dL.

In some embodiments, the dried plasma, when reconstituted, ischaracterized by at least one of: a Factor VII level in the range of30-110 IU/dL, a Factor IX level in the range of 25-135 IU/dL, a ProteinC level in the range of 55-130 IU/dL, and a Protein S level of in therange of 55-110 IU/dL.

In some embodiments, the dried plasma, when reconstituted, ischaracterized by at least one of: a Factor VII level in the range of34-172 IU/dL, a Factor IX level in the range of 70-141 IU/dL, a ProteinC level in the range of 74-154 IU/dL, and a Protein S level of in therange of 61-138 IU/dL.

In some embodiments, the dried plasma, when reconstituted, ischaracterized by at least one of: a Factor V level of at least about 10IU/dL, and a Factor VIII level of at least about 10 IU/dL.

In some embodiments, the dried plasma, when reconstituted, ischaracterized by at least one of: a Factor V level of at least about 30IU/dL, and a Factor VIII level of at least about 25 IU/dL.

In some embodiments, the dried plasma, when reconstituted, ischaracterized by at least one of: a Factor V level of at least about 63IU/dL, and a Factor VIII level of at least about 47 IU/dL.

In some embodiments, the dried plasma, when reconstituted, ischaracterized by at least one of a Factor V level in the range of 63-135IU/dL, a Factor VIII level in the range of 47-195 IU/dL.

In some embodiments, the powder has an average particle size of about 30microns or less. In some embodiments, e the powder has a maximumparticle size of about 100 microns or less.

In some embodiments, the powder includes at least 30% dried protein byweight.

In some embodiments, when reconstituted with 1 mL of fluid per 0.09grams of powder, the reconstituted plasma has a protein concentration inthe range of 35 mg/mL to 60 mg/mL.

In another aspect, an apparatus is disclosed for spray drying plasmaincluding: a plasma source; a pressurized spray gas source; a drying gassource; a spray dry nozzle in sterile fluid communication with theplasma and spray gas sources; a drying chamber in fluid communicationwith the spray dry nozzle and the drying gas source to receive a sprayof plasma from the nozzle for drying; a particle collection deviceconfigured to collect spray dried plasma from an outlet of the dryingchamber; and a collection device gas outlet port in sterile fluidcommunication with the collection device, the gas outlet port includinga sterile outlet port. In some embodiments, the spray nozzle, dryingchamber, and collection device define a sterile isolated interiorvolume.

In some embodiments, the gas outlet port includes a sterile filter.

In some embodiments, the nozzle is in sterile fluid communication witheach of the spray gas source and the drying gas source through arespective sterile filter.

In some embodiments, the gas outlet port is in fluid communication withan external volume through the sterile outlet filter.

In some embodiments, the gas outlet port is in fluid communication withthe drying gas source to provide closed recirculation of the drying gas.

In some embodiments, the plasma source includes a peristaltic pumpconfigured to deliver a flow of plasma to an inlet of the nozzle at aplasma flow rate.

In some embodiments, the spray gas source includes a source ofpressurized non reactive gas, and is configured to deliver the nonreactive gas to the nozzle at a spray gas flow rate.

In some embodiments, the drying gas source includes a source of dryinggas, and is configured to deliver heated drying gas to the nozzle at adrying gas flow rate and an inlet temperature.

Some embodiments include a controller configured to control at least oneselected from the list consisting of: the plasma flow rate, the spraygas flow rate, the drying gas flow rate, and the inlet temperature.

In some embodiments, at least one sensor for measuring outlettemperature information indicative of an outlet temperature the spraydried plasma, the sensor in communication with the controller. In someembodiments, the controller includes a servo loop that controls theoutlet temperature to a selected value by adjusting, based on the outlettemperature information, at least one selected from the list consistingof: the plasma flow rate, the spray gas flow rate, the drying gas flowrate, and the inlet temperature. In some embodiments, the controllerincludes a servo loop that controls the outlet temperature to a selectedvalue by adjusting, based on the outlet temperature information, theplasma flow rate.

In another aspect, an attachment for plasma spray drying apparatusincluding: a plasma inlet port for sterile attachment to a plasmasource; a spray gas inlet port for removable sterile attachment to apressurized gas source; at least one drying gas inlet port for removablesterile attachment to a drying gas source; a spray dry nozzle in fluidcommunication with the plasma and spray gas inlets; a drying chamber influid communication with the attached spray nozzle and drying gas inletto receive a spray of plasma for drying; a particle collection deviceconfigured to collect spray dried plasma from an outlet of the dryingchamber; and a collection device gas outlet port in sterile fluidcommunication with the collection device. In some embodiments, the spraynozzle, drying chamber, and collection device define a sterile isolatedinterior volume.

In some embodiments, at least one of the inlet and outlet ports includesa sterile filter.

In some embodiments, the drying chamber is at least partiallycollapsible.

In some embodiments, the attachment includes a plastic or polymermaterial.

In some embodiments, the particle collection device includes a cyclonechamber.

In some embodiments, the particle collection device includes adetachable storage portion configured to receive collected spray driedplasma.

In another aspect, a product is disclosed including: a physiologicallyactive spray dried plasma powder made using the methods describedherein, e.g., the method described above.

Various embodiments may include any of the above described features,techniques, elements, etc., either alone, or in any suitablecombination.

The plasma spray drying techniques described herein can provide one ormore of the following advantages. An advantage to the plasma spraydrying techniques described herein is that the plasma is not overheatedduring the spray drying process, which increases the recovery rate ofphysiologically functional plasma proteins, thereby increasing theefficacy of the plasma powder. Another advantage to the plasma spraydrying techniques described herein is that the plasma can be stored forfuture use without refrigeration, thereby extending the shelf life andpotential uses of the plasma (e.g., on the battlefield, in space, atsea, etc.). An additional advantage to the plasma spray dryingtechniques described herein is that the process parameters arecontrolled by the output temperature thereby enabling the quantity ofprocessed plasma to be scaled by monitoring the output temperature andadjusting the pump rate and/or the inlet temperature accordingly to meetthe required output temperature for the spray dried plasma.

Other aspects and advantages of the present invention will becomeapparent from the following detailed description, taken in conjunctionwith the accompanying drawings, illustrating the principles of theinvention by way of example only.

BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing and other objects, features, and advantages of the presentinvention, as well as the invention itself, will be more fullyunderstood from the following description of various embodiments, whenread together with the accompanying drawings.

FIGS. 1A-1B are diagrams of exemplary spray drying systems;

FIG. 2 is a diagram of another exemplary spray drying system;

FIG. 3A is a diagram of another exemplary spray drying system;

FIG. 3B is an illustration of a cyclone chamber;

FIGS. 4A-4C are diagrams of exemplary spray nozzles;

FIGS. 5A-5B are diagrams of other exemplary centrifuge systems;

FIGS. 6A-6C are diagrams of exemplary bladder positions for centrifugedevices;

FIGS. 7A-7C are diagrams of exemplary lines for centrifuge devices;

FIG. 8A is a diagram of an exemplary spray dried plasma reconstitutiondevice;

FIG. 8B is a diagram of an exemplary spray dried plasma storage bag;

FIG. 9A is a diagram of an exemplary integrated storage andreconstitution device;

FIG. 9B is a diagram of an exemplary integrated storage andreconstitution device;

FIG. 10 is a flowchart depicting an exemplary spray drying process forplasma;

FIG. 11 is a flowchart depicting another exemplary spray drying processfor plasma;

FIG. 12 is a flowchart depicting an exemplary process of applyingphysiologically active reconstituted plasma to a human patient;

FIG. 13A-13C are diagrams of another exemplary spray drying system;

FIGS. 13D-13F are diagrams of an attachment to a spray drying system;

FIGS. 14A-D are illustrations of air flow configurations for variousspray drying systems;

FIG. 15 is a chart illustrating the physiological activity of freshfrozen plasma, with the following symbol definitions: *from Downes etal. “Serial measurement of clotting factors in thawed plasma for fivedays.” Transfusion 2001; 41:570; †Mean±S. Dak.; ‡Comparison of FactorVIII activity at Day 1 and that at Day 3 was statistically significant;

FIGS. 16A-16D are diagrams illustrating spray dry batch processprocedures;

FIGS. 17A-17B are charts illustrating the results of tests on spraydried plasma.

DETAILED DESCRIPTION

The spray drying system can be utilized to produce physiologicallyactive plasma powder from human plasma. The spray drying system can drythe human plasma to form the physiologically active plasma powder whilenot overheating the human plasma which causes proteins within the humanplasma to lose their efficacy (i.e., denatures the proteins). The spraydrying system can utilize a heating source to heat the human plasma viaa heated air stream. The heating of the human plasma via the heated airstream can remove the moisture from the human plasma while notdenaturing the proteins within the human plasma thereby increasing theefficacy of the physiologically active plasma powder. For example, insome embodiments the moisture is removed by evaporative processes only,and not boiling.

The spray drying system can dry human plasma in a sterile, isolatedenvironment. That is, during the spray drying process, the human plasmaand resulting dried plasma powder can be kept isolated from any nonsterile contaminates. Accordingly, the dried plasma powder product canbe stored for time periods of months or more without the possibility ofthe growth of, e.g., bacterial contaminates.

As used herein, the term physiologically active plasma powder refers toany plasma powder which, when reconstituted, includes proteins that havenot been damaged to such an extent to lose substantially all of theirphysiological efficacy. The physiological activity of a plasma powder,in its reconstituted form, may by indicated by a number of parametersknown in the art including, but not limited to: Prothrombin Time (PT),Activated Partial Thromboplastin Time (aPTT), Fibrinogen level, ProteinC level, and Protein S level. The physiological activity of a plasmapowder, in its reconstituted form, may be indicated by coagulationfactor levels known in the art including, but not limited to: Factor II,Factor V, Factor VII, Factor VIII, Factor IX, and Factor X. Theseparameters may be measured using techniques known in the art, e.g.,using instruments available from DIAGNOSTICA STAGO, Inc. of Five CenturyDrive Parsippany, N.J., 07054.

Devices and techniques described herein may be used to produce plasmapowder which, when reconstituted, has substantially the same level ofphysiological activity as, e.g., native plasma, fresh frozen plasma(FFP), or plasma frozen within 24 hours of phlebotomy (FP24), ThawedPlasma, or Liquid Plasma.

For example, as set forth in the Circular of Information For The Use ofHuman Blood Components (August 2009, available online athttp://www.aabb.org/resources/bct/Documents/coi0809r.pdf) preparedjointly by the Advancing Transfusion and Cellular Therapies Worldwide(AABB), the American Red Cross, America's Blood Centers, and the ArmedServices Blood Program (ASBP), FFP is prepared from a whole blood orapheresis collection and frozen at −18° C. or colder within the timeframe as specified in the directions for use for the relevant bloodcollection, processing, and storage system (e.g., frozen within eighthours of draw). On average, units contain 200 to 250 mL, but apheresisderived units may contain as much as 400 to 600 mL. FFP contains plasmaproteins including all coagulation factors. FFP contains high levels ofthe labile coagulation Factors V and VIII. FFP should be infusedimmediately after thawing or stored at 1 to 6° C. for up to 24 hours. Ifstored longer than 24 hours, the component must be relabeled ordiscarded depending on the method of collection. FFP serves as a sourceof plasma proteins for patients who are deficient in or have defectiveplasma proteins.

FP24 is prepared from a whole blood collection and must be separated andplaced at −18° C. or below within 24 hours from whole blood collection.The anticoagulant solution used and the component volume are indicatedon the label. On average, units contain 200 to 250 mL. This plasmacomponent is a source of non labile plasma proteins. Levels of FactorVIII are significantly reduced and levels of Factor V and other labileplasma proteins are variable compared with FFP. FP24 should be infusedimmediately after thawing or stored at 1 to 6° C. for up to 24 hours. Ifstored longer than 24 hours, the component must be relabeled ordiscarded. This plasma component serves as a source of plasma proteinsfor patients who are deficient in or have defective plasma proteins.Coagulation factor levels might be lower than those of FFP, especiallylabile coagulation Factors V and VIII.

Thawed Plasma is derived from FFP or FP24, prepared using aseptictechniques (closed system), thawed at 30 to 37° C., and maintained at 1to 6° C. for up to 4 days after the initial 24-hour post-thaw period haselapsed. Thawed plasma contains stable coagulation factors such asFactor II and fibrinogen in concentrations similar to those of FFP, butvariably reduced amounts of other factors (e.g., as show in FIG. 15).

Liquid Plasma is separated no later than 5 days after the expirationdate of the Whole Blood and is stored at 1 to 6° C. The profile ofplasma proteins in Liquid Plasma is poorly characterized. Levels andactivation state of coagulation proteins in Liquid Plasma are dependentupon and change with time in contact with cells, as well as theconditions and duration of storage. This component serves as a source ofplasma proteins. Levels and activation state of coagulation proteins arevariable and change over time.

FFP and FP24 are indicated in the following conditions: management ofpreoperative or bleeding patients who require replacement of multipleplasma coagulation factors (e.g., liver disease, DIC); patientsundergoing massive transfusion who have clinically significantcoagulation deficiencies; patients taking warfarin who are bleeding orneed to undergo an invasive procedure before vitamin K could reverse thewarfarin effect or who need only transient reversal of warfarin effect;for transfusion or plasma exchange in patients with thromboticthrombocytopenic purpura (TTP); management of patients with selectedcoagulation factor deficiencies, congenital or acquired, for which nospecific coagulation concentrates are available; management of patientswith rare specific plasma protein deficiencies, such as C1 inhibitor,when recombinant products are unavailable.

Thawed Plasma is indicated for: management of preoperative or bleedingpatients who require replacement of multiple plasma coagulation factorsexcept for patients with a consumptive coagulopathy; initial treatmentof patients undergoing massive transfusion who have clinicallysignificant coagulation deficiencies; and patients taking warfarin whoare bleeding or need to undergo an invasive procedure before vitamin Kcould reverse the warfarin effect or who need only transient reversal ofwarfarin effect. Thawed Plasma should not be used to treat isolatedcoagulation factor deficiencies where other products are available withhigher concentrations of the specific factor(s).

Liquid Plasma is indicated for initial treatment of patients who areundergoing massive transfusion because of life-threateningtrauma/hemorrhages and who have clinically significant coagulationdeficiencies.

Various embodiments of plasma powder of the type described herein, mayexhibit levels of physiological activity equivalent or superior to FFPor FP24, and thus may be suitable, e.g., for the uses of Liquid Plasma,Thawed Plasma, FP24, and FFP, as described above. For example, FIG. 15shows the coagulation factor activity for thawed plasma derived from FFPfor several coagulation factors. Plasma powder of the type describedherein may exhibit substantially similar coagulation activity for one ormore or all of the listed factors.

Various embodiments of plasma powder of the type described herein, mayexhibit a PT (in seconds) of 48 or less, 31 or less, 15 or less, etc.For example, the plasma powder may have a PT (in seconds) in the rangeof 10-48, in the range of 14-31, in the range of 10-15, etc.

Various embodiments of plasma powder of the type described herein, whenreconstituted, may exhibit an aPTT (in seconds) of 95 or less, 66 orless, 35 or less, etc. For example, the plasma powder may have an aPTT(in seconds) in the range of 30-95, in the range of 28-66, in the rangeof 30-35, etc.

Various embodiments of plasma powder of the type described herein, whenreconstituted, may exhibit a Fibrinogen level (in mg/dL) of 100 or more,110 or more, 223 or more, etc. For example, the plasma powder may have aFibrinogen level (in mg/dL) in the range of 100-500, in the range of110-300, in the range of 223-500, etc.

Various embodiments of plasma powder of the type described herein, whenreconstituted, may exhibit a Protein C level (in IU/dL) of 54 or more,55 or more, 74 or more, etc. For example, the plasma powder may have aProtein C level (in IU/dL) in the range of 54-154, in the range of55-130, in the range of 74-154, etc.

Various embodiments of plasma powder of the type described herein, whenreconstituted, may exhibit a Protein S level (in IU/dL) of 56 or more,55 or more, 61 or more, etc. For example, the plasma powder may have aProtein S level (in IU/dL) in the range of 56-138, in the range of55-110, in the range of 61-138, etc.

Various embodiments of plasma powder of the type described herein, whenreconstituted, may exhibit a Factor V level (in IU/dL) of 17 or more, 30or more, 54 or more, etc. For example, the plasma powder may have aFactor V level (in IU/dL) in the range of 17-135, in the range of30-110, in the range of 63-135, etc.

Various embodiments of plasma powder of the type described herein, whenreconstituted, may exhibit a Factor VII level (in IU/dL) of 31 or more,30 or more, 54 or more, etc. For example, the plasma powder may have aFactor VII (in IU/dL) level in the range of 31-172, in the range of30-110, in the range of 54-172, etc.

Various embodiments of plasma powder of the type described herein, whenreconstituted, may exhibit a Factor VIII level (in IU/dL) of 10 or more,25 or more, 47 or more, etc. For example, the plasma powder may have aFactor VIII (in IU/dL) level in the range of 10-195, in the range of25-90, in the range of 47-195, etc.

Various embodiments of plasma powder of the type described herein, whenreconstituted, may exhibit a Factor IX level (in IU/dL) of 13 or more,25 or more, 70 or more, etc. For example, the plasma powder may have aFactor IX level (in IU/dL) in the range of 13-141, in the range of25-135, in the range of 70-141, etc.

Various embodiments of the plasma powder may exhibit any combination ofthe above activity levels.

Some embodiments of plasma powder of the type described herein may be adry powder containing, e.g., less than 1% moisture by weight, less than5% moisture by weight, less than 10% moisture by weight, etc. Someembodiments may have powder with moisture content in the range, e.g., of3-5% moisture by weight.

Various embodiments of plasma powder of the type described herein, maybe a fine powder having an average particle size less than 100 microns,less than 50 microns, less than 30 microns, less than 10 microns, lessthan 5 microns, less than 1 micron, etc. For example, the powder mayhave an average particle size in the range of 1-30 microns. In someembodiments, the powder has a maximum particle size of less than 100microns, less than 50 microns, less than 30 microns, less than 10microns, less than 5 microns, less than 1 micron, etc. For example, thepowder may have a maximum particle size in the range of 1-30 microns.Such fine powders may advantageously be reconstituted quickly andefficiency, e.g., using the reconstitution techniques described herein.

Various embodiments of plasma powder of the type described herein may becomposed of 10% or more, 20% or more, 30% or more, 40% or more, 50% ormore dried proteins by weight. In some embodiments, when reconstitutedat a ratio of 0.09 grams of powder to 1 mL of reconstituting fluid, thereconstituted plasma has a protein concentration ration of about 48mg/mL, e.g., in the range of 45-55 mg/mL.

Advantageously, embodiments of the dried plasma powders described hereinmay be stored for extended storage times while maintaining a high levelof physiological activity. Various embodiments of plasma powder of thetype described herein may be stored in a closed sterile container (e.g.,a sealed sterile bag) for a storage time, and then, upon reconstitution,exhibit any of the levels of physiological activity set forth above. Forexample, in various embodiments, the stored powder storage time may beup to 1 day, 1 week, 1 month, 2 months, 3 months, 4 months, 5 months, 6months, 7 months, 8 months, 9 months, 1 year, 2 years, 5 years, or evenlonger. After the storage time, the powdered may be reconstituted toform a reconstituted plasma having level of physiological activity equalto or greater than, e.g., Liquid Plasma, Thawed Plasma, FP24, or FFP.Various embodiments of the dried plasma, during storage experience arate of degradation (i.e., loss of physiological activity) comparable orless than that of e.g., Liquid Plasma, Thawed Plasma, FP24, or FFP.

FIG. 1A is a diagram of an exemplary spray drying system 100 a forproducing plasma powders of the type described above. The system 100 aincludes a spray drying apparatus 140 a. A blood donor 110 a donatesblood 125 a via a blood collection device 120 a. The blood collectiondevice 120 a (e.g., needle and bag, etc.) collects blood 125 a from ablood donor 110 a (e.g., human). A fluid processing device 130 aprocesses the blood 125 a to separate plasma 135 a from the blood 125 a(e.g., a centrifuge device, a reactant, etc.).

The plasma 135 a is transferred to the spray drying apparatus 140 a(e.g., a pump, gravity, etc.). The spray drying apparatus 140 a producesphysiologically active plasma powder 145 a via the spray dryingtechniques described herein. The physiologically active plasma powder145 a is stored in a spray dried plasma storage device 150 a (e.g., aplastic bag, a glass container, a sealed bag, a sealed container, etc.).

A spray dried plasma reconstitution device 160 a reconstitutes thephysiologically active plasma powder 155 a with a reconstitution fluid(e.g., water, glycine, saline solution, a buffer solution, a bloodsubstitute, etc.) to form physiologically active reconstituted plasma165 a. In some embodiments, two reconstitution fluids can be used; e.g.,in one embodiment, a mixture of distilled Water and 1.5% (200 mMglycine) (available from Baxter International Inc. of Deerfield, Ill.)is used.

The plasma powder 145 a may exhibit, a recovery rate for the proteinbetween the plasma and the physiologically active reconstituted plasma,of at least 50%, at least 60%, at least 70%, at least 80%, at least 90%,etc. In some embodiments, the reconstituted plasma has protein levelscomparable to or better than FFP or FP24. The physiologically activereconstituted plasma 165 a is administered to a plasma recipient 170 a(e.g., via an intravenous injection, applied to a wound on the plasmarecipient, etc.).

In other embodiments, the blood collection device 120 a and the fluidprocessing device 130 a are an integrated device that collects theblood, separates the plasma from the blood, and returns the remainingparts of the blood back to the blood donor 110 a. This process can bereferred to as apheresis and can, for example, utilize an apheresisdevice.

FIG. 1B is a diagram of an exemplary spray drying system 100 b. Thesystem 100 b includes a spray drying apparatus 140 b. A blood collectiondevice 120 b (e.g., needle and bag, etc.) collects blood 125 b from ablood donor 110 b (e.g., human).

A fluid processing and washing device 130 b processes the blood 125 b toseparate plasma 132 b from the blood 125 b (e.g., a centrifuge device, areactant, etc.). The fluid processing and washing device 130 b washesthe plasma 132 b to remove one or more antigens (e.g., virus, allergen,etc.). The washing of the plasma 132 b by the fluid processing andwashing device 130 b can reduce the antigens on the plasma 132 b by afactor of at least 100, or at least 10³, or at least 10⁴, or at least10⁵.

The fluid processing and washing device 130 b transfers the plasma 135 athrough a ultraviolet device 134 b and a fluid filter 136 b (e.g., apump, gravity, etc.). The ultraviolet device 134 b irradiates the plasma132 b with ultraviolet radiation to destroy one or more antigens (e.g.,virus, allergen, etc.). The irradiation of the plasma 132 b by theultraviolet radiation can reduce the antigens on the plasma 132 b by afactor of at least 100, or at least 10³, or at least 10⁴, or at least10⁵. The fluid filter 136 b filters one or more antigens from the plasma132 b (e.g., biofilter, activated charcoal filter, etc.). The filteringof the plasma 132 b by the fluid filter 132 b can reduce the antigens onthe plasma 132 b, e.g., by a factor of at least 100, or at least 10³, orat least 10⁴, or at least 10⁵. An advantage of washing, irradiating,and/or filtering the plasma 132 b is that this process cleans the plasma132 b so that a plurality of units of plasma can pooled together forprocessing by the spray drying apparatus 140 b, thereby increasing theefficiency of the spray drying processing by allowing more plasma to bespray dried during a drying cycle. After the plasma 132 b is processedby the ultraviolet device 134 b and the fluid filter 136 b, filteredplasma 138 b is transferred to the spray drying apparatus 140 b.

The spray drying apparatus 140 b produces physiologically active plasmapowder 145 b via the spray drying techniques described herein. Thephysiologically active plasma powder 145 b is stored in a spray driedplasma storage device 150 b (e.g., a plastic bag, a glass container, asealed bag, a sealed container, etc.).

A spray dried plasma reconstitution device 160 b reconstitutes thephysiologically active plasma powder 155 b with a reconstitution fluid(e.g., water, glycine, any suitable irrigation fluid, a bloodsubstitute, etc.) to form physiologically active reconstituted plasma165 b. The physiologically active reconstituted plasma 165 b isadministered to a plasma recipient 170 b (e.g., via an intravenousinjection, applied to a wound on the plasma recipient, etc.).

In some embodiments, the reconstitution fluid includes glycine. Notwishing to be bound by theory, in some embodiments, it is believed thatthe glycine can enable the physiologically active reconstituted plasma165 b to act as a volume expander and can increase the efficacy of theplasma. In some embodiments, the glycine may advantageously affect thepH level of the reconstituted plasma, thereby increasing the efficacy ofthe plasma. In one embodiment, the reconstitution fluid includes 1.5%glycine. In other embodiments, reconstitution fluid includes glycineconcentrations of 0.1%, 0.5%, 1.0%, 1.25%, 1.3%, 1.4%, 1.6%, 1.7%,1.75%, 2%, 2.5%, 3%, 4%, or 5%. As discussed in greater detail below, insome embodiments, plasma powder reconstituted with glycine exhibitsimproved PT, aPTT, and coagulation factor levels in comparison to plasmapowder reconstituted with water.

In various embodiments, other reconstitution fluids may be usedincluding, e.g., solutions including a buffering agent (e.g., aphosphate buffer, HC1, buffer Citric Acid buffer, etc.). As withglycine, these reconstitution fluids may be used to adjust the pH levelof the reconstituted plasma to a desired value or range. For example, insome embodiments, the spray dried plasma may have a pH level whichdiffers from native plasma, and a buffering agent may be used to adjustthe pH level of the reconstituted plasma to more closely match that ofthe native plasma.

FIG. 2 is a diagram of another exemplary spray drying system 200. Thesystem 200 receives plasma stored in a plasma storage device 210 andincludes a centrifuge device 230, a spray drying apparatus 240. Thesystem 200 stores plasma powder in a plasma powder storage device 290.The spray drying apparatus 240 includes a pump device 242, a heated airstream device 244, a gas supply device 246, a spray nozzle 248, a spraychamber 250, a cooling/heating device 252, a particle collection device254, a vacuum device 256, and an output optimization device 258.

The centrifuge device 230 centrifuges the plasma stored in a plasmastorage device 210 to maximize the delivery of particular particles ofthe plasma to the spray drying apparatus 240 (e.g., platelets, protein,type of plasma, etc.). The centrifuge device 230 moves the centrifugedplasma to the spray drying apparatus 240 (e.g., directly via a pump,indirectly via gravity, etc.). Although FIG. 2 illustrates the system200 including the centrifuge device 230, in some embodiments of thesystem 200, the centrifuge device 230 is not included in the system 200.For example plasma obtained from any suitable source/supplier can beinput into the spray drying system.

The pump device 242 pumps the plasma to the spray nozzle 248 at a setpump setting (e.g., corresponding to a flow rate of about 11.5 mL/min,in the range of 9 to 15 mL/min, etc.). In some embodiments, the plasmacan be combined with the reagent or any other type of substance (e.g.,blood thinner, water, glycine, blood substitute, etc.) prior to exitingthe nozzle 248. In other embodiments, the plasma is not combined withany substance.

The heated air stream device 244 provides a heated, dehumidified airstream to the spray nozzle 248 (e.g., 107° C. at 5% humidity, 109° C. at25% humidity, etc.). Some embodiments, e.g., as described below, mayinclude a separate heater and dehumidifier for providing the heateddehumidified stream of air.

The gas supply device 246 provides a non reactive gas (e.g., nitrogen,air, carbon dioxide, helium, etc.) at a spray flow rate (e.g.,continuous, intermittent, etc.) to the spray nozzle 248. As used herein,a non reactive gas is one which does not chemically react with theplasma or heated air stream during the operation of the spray dryingsystem. The non reactive gas may be, e.g., an inert gas, or a non inertgas which does not react under the operating conditions of the system.In one embodiment, the spray nozzle 248 combines the non reactive gasand the plasma to atomize the plasma into the spray chamber 250. Thespray cone of atomized plasma exiting the nozzle 248 is treated by theheated air stream, to dry the atomized particles.

The cooling/heating device 252 or separate heating or cooling devicescan heat and/or cool parts of the spray chamber 250 (e.g., to removeremaining moisture, to stop the denaturing of the proteins in theplasma, etc.). The particle collection device 254 collects the spraydried plasma utilizing the vacuum device 256 (e.g., via a cycloneaffect). For example, the vacuum device 256 creates a vacuum that pullsthe atomized particles into the particle collection device 254 (e.g.,particle filter, cyclone trap, etc.). The physiologically active plasmapowder is stored in a plasma powder storage device 290. Additionally oralternatively, a pump or other similar devices may be used to provideair flow to move the particles through the collection device 254.

The output optimization device 258 measures the output temperature ofthe atomized particles after they have been emitted from the spraynozzle 248, e.g., as they enter the spray chamber 250, at the interfacebetween the spray chamber 250 and the collection device 254, or atanother suitable position. In some embodiments, the temperature of theparticles is not measured directly; instead, an indirect indicator(e.g., an outlet gas temperature) is measured. The temperature of theatomized particles is maintained below a threshold temperature toprevent denaturing of the proteins within the plasma. The outputtemperature is not directly adjustable. The output optimization device258 can adjust the pump setting of the pump device 242 and/or the inputtemperature of the heated air stream device 244 to maintain the outputtemperature in a selected temperature range.

In some embodiments, the pump setting of the pump device 242 isdynamically adjusted based on the input temperature of the plasma at thespray nozzle 248 and/or the output temperature of the spray dried plasmapowder at the spray chamber 250 and/or at the particle collection device254.

FIG. 3A is a diagram of another exemplary spray drying system 300. Thesystem 300 includes a spray drying apparatus 340. The spray dryingapparatus 340 includes a peristaltic feed pump 342, adehumidifier/heated air supply 344, a non reactive gas supply 346, anozzle 348, a drying chamber 350, an inlet temperature device 352, anoutlet temperature device 354, spray dried particles 356, a cyclonechamber 358, a powder collection chamber 360, a filter 362, and a vacuumsupply 364.

The peristaltic feed pump 342 pumps plasma 310 at a pump rate (e.g.,continuous, intermittent, etc.) to the nozzle 348. Thedehumidifier/heated air supply 344 heats and/or dehumidifies air, outputfrom the vacuum supply 364 and blows a heated, dehumidified air streamat an inlet temperature to the nozzle 348. Preferably the temperature ofthe air stream is adjustable. The non reactive gas supply 346 supplies anon reactive gas (e.g., nitrogen, helium, carbon dioxide, air, etc.) tothe nozzle 348 at a flow rate (e.g., continuous, intermittent, etc.). Inone embodiment, the non reactive gas supply 346 is a pressured tank ofthe non reactive gas with a regulator. In another embodiment, the nonreactive gas supply 346 is a pump for pressurizing the non reactive gas.The plasma 310, the heated dehumidified air stream, and the non reactivegas are combined at the nozzle 348 and the atomized plasma is blown intothe drying chamber 350.

The spray dried particles 356 are moved into the cyclone chamber 358 viathe vacuum created by the vacuum supply 364 for cyclonic separation.Cyclonic separation is a method of removing particulates from an air,gas or water stream, without the use of filters, through vortexseparation. Rotational effects and gravity are used to separate mixturesof solids and fluids. In some embodiments, the cyclone chamber 358 is acylindrical body with a tapered conical bottom portion. As shown in FIG.3B, rotating (air) flow is established within the cyclone chamber 358.Air flows in a spiral pattern, beginning at the top (wide end) of thecyclone chamber and ending at the bottom (narrow) end before exiting thecyclone in a straight stream through the center of the cyclone and outthe top. Larger (denser) particles in the rotating stream have too muchinertia to follow the tight curve of the stream and strike the outsidewall, falling then to the bottom of the cyclone where the particles forma powder that can be collected and removed. In a conical system, as therotating flow moves towards the narrow end of the cyclone the rotationalradius of the stream is reduced, separating smaller and smallerparticles. The cyclone geometry, together with flow rate, defines thecut point of the cyclone. This is the size of particle that will beremoved from the stream with a 50% efficiency. Particles larger than thecut point will be removed with a greater efficiency, and smallerparticles with a lower efficiency. In some embodiments, the surfaces ofthe cyclone chamber 358 may be treated to avoid adherence of theparticles to the walls of the containers, e.g., due to electrostaticeffects, by methods and compositions known in the art (e.g., silicone,Teflon, etc.).

Due to the cyclone effect within the cyclone chamber 358, the spraydried particles 356 are collected within the powder collection chamber360 and other particles are collected by the filter 362 (e.g., a highefficiency particulate air (HEPA) filter, a carbon filter, etc.).

In other embodiments, other particle collection devices may be usedincluding, e.g., an electrostatic particle trap, a gravity basedparticle trap, a filter, etc.

The physiologically active plasma powder 390 is collected from thepowder collection chamber 360 and can be, for example, stored (e.g., viastorage container, etc.) and/or used (e.g., applied to a wound of ahuman, etc.).

In other embodiments, the powder collection chamber 360 is removablefrom the spray drying apparatus 340.

In some embodiments, the processing of the plasma by the spray dryingapparatus 340 is an isolated sterile system. In other words, after thespray drying apparatus 340 starts processing the plasma 310, there is nointroduction of any further liquids, solids, and/or gases into the spraydrying apparatus 340 that could contaminate the plasma powder. Such asystem enables the spray drying apparatus 340 to remain sterile duringthe processing of the plasma 310.

In some embodiments, the spray drying apparatus 340 operates in a smallbatch mode. In the small batch mode, the spray drying apparatus 340 canprocess, e.g., one 400 mL of plasma (e.g., one unit of plasma from asingle donor). In this mode of operation, the lines, drying chamber 350,the cyclone chamber 358, and/or the powder collection chamber 360 can becleaned (e.g., sterilized, dipped in an alcohol bath, wiped by analcohol wipe, etc.) between processing batches.

In some embodiments, the spray drying apparatus 340 operates in a largebatch mode. In the large batch mode, the spray drying apparatus 340 canprocess, e.g., hundreds of mL of plasma (e.g., multiple units of plasmafrom a plurality of donors). In this mode of operation, the units ofplasma are pooled together for processing. An advantage to the spraydrying apparatus 340 is that the units of plasma can be pooled togetherand then cleaned via the fluid processing and washing device 130 b, theultraviolet device 134 b, and/or the fluid filter 135 b to provide asafe spray dried plasma powder while reducing the overhead of cleaningthe spray drying apparatus 340 between batches. Alternatively, asdescribed in greater detail below, the system may include one or moredisposable portions that may be swapped out for new sterile counterpartsbetween batches.

FIG. 4A is a diagram of an exemplary spray nozzle 440 a in a spraydrying apparatus 400 a. The apparatus 400 a includes adehumidifier/heated air supply 410 a, a heated air line 415 a, aperistaltic feed pump 420 a, a plasma line 425 a, a non reactive gassupply 430 a, and a non reactive gas line 435 a. The dehumidifier/heatedair supply 410 a heats and/or dehumidifies air and pumps the heated airthrough the heated air line 415 a to the nozzle 440 a. The peristalticfeed pump 420 a pumps plasma through the plasma line 425 a to the nozzle440 a. The non reactive gas supply 430 a supplies a non reactive gasthrough the non reactive gas line 435 a to nozzle 440 a. The nonreactive gas, the plasma, and the heated air are combined at the end ofthe nozzle 440 a and the atomized particles 450 a exit the nozzle 440 a.

In some embodiments, the heated air line 415 a may include a sterilefilter (e.g., a filter that removes microorganisms, particles,precipitates, and undissolved powders larger than 0.22 micron) locatedbetween the air supply 410 a and the spray nozzle 440 a. Similarly, asterile filter may be positioned along the non reactive gas line 435 aand the spray nozzle 440 a. In various embodiments, the nozzle inputlines 415 a, 425 a, and 435 a may include detachable connections to theair supply 410 a, the pump 420 a, the gas supply 430 a.

FIG. 4B is a diagram of an exemplary spray nozzle 440 b in a spraydrying apparatus 400 a. A heated air stream 415 b from the heated airline 415 a and a plasma and non reactive gas mixture 437 b from theplasma line 425 a and the non reactive gas line 435 a is output from thespray nozzle 440 b. In this embodiment, the output of the heated airstream 415 b is via a circular output port that surrounds the output ofthe plasma and non reactive gas mixture 437 b. Note that, although oneconfiguration is shown, other configurations may be used. For example,in some embodiments, the output port for the plasma and non reactive gasmixture 437 b is smaller than the output of the heated air stream 415 b.

FIG. 4C is a cross section diagram of the tip 450 c of spray nozzle 440b showing the mixture of plasma and non reactive gas to atomize theplasma. The tip includes a first channel 452 c that delivers a flow ofplasma to the end of the nozzle tip 450 c. A second channel 454 c isdisposed concentrically about the first channel. The second channel 454c delivers non reactive gas to the end of the tip, where it mixes withthe flow of plasma. As described above, the atomized plasma may then bemixed with the heated air stream 415 b for drying. The mixture of plasmaand non reactive gas exits a nozzle output port 456 c as an atomizedplasma spray. The tip 450 c may include a central member 458 c locatedwithin and extending along the first channel 452 c to an end located inor near the nozzle output port 456 c. The end of the central member 458c may include a feature 459 c which facilitates the atomization of theplasma. The feature 459 c (or other portions of the nozzle tip) may bemade of a material which resists the build up of residue at the nozzleoutput port, e.g., ruby.

As illustrated in this example, the plasma and the non reactive gas aremixed together before the air stream mixes into the mixed plasma and thenon reactive gas. In some embodiments, the mixture of the non reactivegas and the plasma atomizes the plasma into a spray. In someembodiments, the mixture of the heated air stream into the atomizedparticles of the plasma removes the moisture and dries the atomizedparticles to form spray dried plasma particles. Note that although inthe example above, the heated air stream is directed in substantiallythe same direction as the atomized plasma, in some embodiments theheated air stream may be oriented in other directions (e.g., counter tothe flow of the atomized plasma). In some embodiments the heated airflow may emanate from a port located at a position in the drying chamberother than on the nozzle.

FIG. 5A is a diagram of an exemplary centrifuge system 500 a. The system500 a includes plasma 510, a centrifuge device 530 a, and a spray dryingapparatus 540. The centrifuge device 530 a includes a centrifuge housing532 a, a line 534, a bladder 536, an air supply device 538, and a motor539.

The centrifuge housing 532 a rotates, via the motor 539 (e.g., directdrive system, indirect drive system, etc.), to provide inertial forcesfor the separation of the plasma 510 that is pumped and/or travels(e.g., gravity fed, etc.) through the line 534. The air supply device538 inflates and/or deflates the bladder 536 to provide for main linegeometry as described herein.

Although FIG. 5A depicts the air supply device 538 included in thecentrifuge housing 532 a, the air supply device 538 can be positioned atany place within or remotely located from the centrifuge housing 532 a.

FIG. 5B is a diagram of another exemplary centrifuge system 500 b. Thesystem 500 b includes plasma A 512 a, plasma B 512 b, a centrifugedevice 530 b, a spray drying apparatus A 545 a, and a spray dryingapparatus B 545 b. The centrifuge device 530 b includes a centrifugehousing 532 b, a line A 535 a, a line B 535 b, a bladder A 537 a, and abladder B 537 b.

The centrifuge housing 532 b rotates to provide centrifugal forces forthe separation of the plasma A 512 a and the plasma B 512 b that ispumped and/or travels (e.g., gravity fed, etc.) through the line A 535 aand B 535 b, respectively. An air supply device (not shown) inflatesand/or deflates each bladder A 537 a and B 537 b to provide for mainline geometry for each of the lines A 535 a and B 535 b, respectively,as described herein.

In other embodiments, a plurality of bladders are located in paralleland in close proximate to the line A 535 a. For example, the line A 535a is approximately located to four bladders (i.e., along the main line:Bladder A is positioned at 2 cm, Bladder B is positioned at 4 cm,Bladder C is positioned at 6 cm, and Bladder D is positioned at 8 cm)and each bladder can modify the geometry of the line A 535 a approximateto the location of the bladder.

FIG. 6A is a diagram of an exemplary bladder position A 636 a for line A634 a in a centrifuge device 530 of FIG. 5. The geometry of the line A634 a functions as a typical centrifugal sedimentation chamber, in whichthe target biological components are retained in the curve while nontarget components pass (i.e., Bladder Position 0).

FIG. 6B is a diagram of an exemplary bladder position B 636 b for line B634 b in a centrifuge device 530 of FIG. 5. The geometry of the line B634 b functions as a compression chamber, which holds and compresses thetarget biological component (i.e., Bladder Position +1).

FIG. 6C is a diagram of an exemplary bladder position C 636 c for line C634 c in a centrifuge device 530 of FIG. 5. The geometry of the line C634 c functions to maximize target component recovery (i.e., BladderPosition 1).

FIG. 7A is a diagram of an exemplary line A 734 a for a centrifugedevice 530 of FIG. 5. The line A 734 a includes a plurality of fluidlumens 735 a, 736 a, and 737 a.

FIG. 7B is a diagram of an exemplary line B 734 b for a centrifugedevice 530 of FIG. 5. The line B 734 b includes a plurality of fluidlumens 735 b and 736 b.

FIG. 7C is a diagram of an exemplary line C 734 c for a centrifugedevice 530 of FIG. 5. The line C 734 c includes a plurality of fluidlumens 735 c and 736 c.

FIG. 13A illustrates a spray drying system 1300, featuring a disposableattachment 1301. FIG. 13B is a schematic of the components of system1300 with the attachment 1301 attached. FIG. 13C is a schematic ofcomponents of system 1300 with the attachment 1301 removed. FIG. 13D isa schematic of the attachment 1301 alone.

The system 1300 includes a plasma source 1302, as shown, a bag of freshor thawed frozen plasma pumped through a plasma line 1303 by aperistaltic pump 1304. The system further includes a drying gas source1305 including a pump 1305 a and a heater 1305 b for supplying thedrying gas (e.g., heated dry air). The system also includes a nonreactive spray gas source 1320, e.g., a source of pressurized nitrogengas.

Disposable attachment 1301 (shown in detail in FIGS. 13D-13F) includesspray nozzle assembly 1307 having a spray nozzle 1321 and a plasma input1308 for sterile coupling to the plasma source 1302. For example, asshown, the plasma input includes a feed tube 1303 with a sealed end forsterile connection to the plasma unit. In other embodiments, other typesof sterile connectors or docks may be used.

The nozzle assembly 1307 also includes a drying gas input 1309 forconnection to the drying gas source 1305. The drying gas connection is asterile connection, e.g., including a sterile filter. The nozzleassembly also includes a spray gas input 1319 for sterile connection tothe spray gas source 1320 (e.g., as shown, a nitrogen). In someembodiments, the spray gas connection includes a sterile filter.

The attachment 1301 also includes a drying chamber 1310, a collectiondevice 1311, and a storage container 1312. As in the spray dryingsystems above, plasma, drying gas, and spray gas are combined at a spraynozzle of the nozzle assembly, and sprayed into drying chamber 1310.Dried plasma powder is collected by the collection device 1311 (as showna cyclone chamber) and transferred to the storage container 1302. Thecollection device includes a gas output port 1313 which connects back tothe main body of the spray drying system 1300 through a sterile filter.Gas from the output port is directed to an air conditioner 1314 whichdehumidifies the gas, and circulates the dried gas back to the dryinggas source 1305. Waste fluid produced during the dehumidification isdirected to a waste fluid storage container 1315

Attachment 1301 includes a sterile isolated spray drying environmentwhich connects to the main body of the spray drying system only throughsterile connections. Accordingly, after a spray drying run, a freshisolated sterile spray drying environment can be obtained by simplyremoving the attachment 1301 and replacing it with a unused attachment.The new attachment 1301 need only be connected to the main body of thesystem 1300, and nothing on the main body of the system 1301 requiressterilization. Accordingly, the system 1301 can be quickly changed overbetween spray drying runs, allowing for the efficient production ofdried plasma powder.

One or more portions of the attachment 1301 may be collapsible forefficient storage. For example, in some embodiments, the drying chamber1310 is collapsible, e.g., in an accordion fashion. One or more portionof attachment 1301 may be made of a plastic or polymer material, orother suitable material (e.g., chosen for light weight, low cost, easeof fabrication, etc.).

In some embodiments, system 1300 includes a mechanism for positivelyidentifying the attachment 1301 as an appropriate attachment for thesystem. The mechanism may include a bar code reader, an RFID system,etc. In one embodiment, the attachment 1310 includes a microchip thatstores an encrypted code which is read by the system 1300 to verify theidentity of the attachment 1301.

In some embodiments, system 1300 includes one or more sensors,interlocks, etc., to confirm the proper attachment of the attachment1301. In some embodiments, the sensors are in communication with acontroller which prevents operation of the system 1300 in the event ofimproper or incomplete attachment.

As shown, spray dry system 1300 includes a device 1316 for automaticsealing and removal of the storage container 1312. The device 1316 mayinclude an automated clamping and cutting mechanism, to seal of thecontainer 1312 and remove it from the attachment 1301.

FIGS. 14A-14D illustrate various air flow configurations for the spraydry systems of the types described herein. Referring to FIG. 14A, in oneembodiment, a pump 1401 receives dry air and directs a stream of dry airto heater 1402 for heating. The heated dry air passes through sterilefilter 1403, and through a spray nozzle (not shown) into a sterile,isolated drying and particle collection chamber 1404. The air stream isoutput through a second filter 1405 to an air conditioning unit 1406 fordehumidification. Dry air from the air conditioning unit 1406 is drawnin to pump 1401 to begin the cycle again. Accordingly, the air stream isrecirculated in a closed loop fashion.

Referring to FIG. 14B, in another embodiments, the pump 1401 is locatedon the output side of drying and collection chamber 1404. The pump 1401draws air out of the chamber 1404 through the filter 1405, and directsthe air stream to the air conditioning unit 1406 for dehumidification.Dry air from the air conditioning unit 1406 is directed through theheater 1402 and through the filter 1403 into the drying and collectionchamber 1404. Accordingly, the air stream in recirculated in a closedloop fashion.

Referring to FIG. 14C, in another embodiment, the air stream is notrecirculated in a closed loop. The pump 1401 draws in room air, anddirects an air stream to the air conditioning unit 1406 fordehumidification. Dry air from the air conditioning unit 1406 isdirected through the heater 1402 and through the filter 1403 into thedrying and collection chamber 1404. Air output from the chamber 1404passes through the filter 1405 and is exhausted to an externalenvironment.

Referring to FIG. 14D, in another embodiment, the air stream is againnot recirculated in a closed loop. In this case, the pump 1401 islocated on the output side of the drying and collection chamber 1404.The pump 1401 provides negative pressure which draws room air into theair conditioning unit 1406 for dehumidification. Dry air from the airconditioning unit 1406 is directed through the heater 1402 and throughthe filter 1403 into the drying and collection chamber 1404. Air isdrawn out through the filter 1405 to the pump 1401, and is exhausted toan external environment.

Note that in each of the configurations shown in FIGS. 14A-14D, the airstream passes into and out of the drying and collection chamber 1404through sterile filters. Accordingly, the chamber is maintained as anisolated sterile environment (as indicated by the dotted box). This isthe case both for the closed loop recirculating configurations shown inFIGS. 14A-14B, and the open non circulating air stream configurationsshown in FIGS. 14C-14D.

In various embodiments, spray drying systems as described herein producewaste fluid as a byproduct of the drying process. In some embodiments(e.g., in the system shown in FIG. 13A), the waste fluid is collected ina detachable receptacle, which can be discarded using the standardprotocols for disposal of biomedical waste. In some embodiments, thespray drying system may be connected (e.g., hard or soft plumbed) to atreatment facility which receives and treats waste fluid from thesystem. In some embodiments, the spray drying system may include one ormore waste treatment devices for treating the waste fluid. For example,the system may include a reservoir of treatment material (e.g., chlorinebleach), which may be mixed with the waste fluid to render it safe fordisposal in a standard sewer system. In some such embodiments, thesystem may be connected (e.g., hard or soft plumbed) to the sewersystem.

In various embodiments, the spray drying systems as described herein mayinclude a process tracking and management capability. For example, insome embodiments, the system may include a device (e.g., bar codereader, RFID reader, etc.) that reads information. The information mayinclude the identity, type, lot, etc. of plasma units input into thesystem, the identity, type, lot, etc of output dried plasma powderunits, etc. This information may be processed and/or recorded using aprocessor (e.g., a general purpose computer) and/or a memory (e.g., ahard drive). The system may include a device (e.g., a printer) formarking input plasma or output dry plasma units with identifyinginformation.

In various embodiments, spray drying systems as described herein may beconnected, e.g., via a local area network, wide area network, theinternet, etc.) to one or more external systems, databases, etc. Forexample the spray drying system may communicate with one or morecomputer systems or databases of blood centers for the purpose ofprocess tracking and management. In some embodiments, the operation ofthe spray drying system may be controlled remotely. For example, in someapplications, the spray drying system could be switched on or off orotherwise controlled in response to information regarding the currentlocal need for plasma products.

FIG. 8A is a diagram of an exemplary spray dried plasma reconstitutiondevice 860 in reconstitution system 800. The system 800 includesphysiologically active plasma powder 840, the spray dried plasmareconstitution device 860, and physiologically active reconstitutedplasma 890. The spray dried plasma reconstitution device 860 includesreconstitution fluid 850 and a mixer device 862 (e.g., agitation device,mixing blades, etc.).

The physiologically active plasma powder 840 and the reconstitutionfluid 850 is provided to the mixer device 862. The mixer device 862mixes (e.g., rocking, agitation, physical movement, blades, shaking,vibration, etc.) the physiologically active plasma powder 840 and thereconstitution fluid 850 (e.g., 100 mL, 200 mL, 300 mL, 400 mL, 500 mL,600 mL, 700 mL, 800 mL, 900 mL, 1000 mL, etc.) to form thephysiologically active reconstituted plasma 890. The mixer device 862can mix the physiologically active plasma powder 840 and thereconstitution fluid 850 for a predefined (e.g., thirty seconds, twominutes, etc.) and/or a variable time period (e.g., variable time periodbased on an optical sensor that measures the mixing of the substances,etc.).

In some embodiments, the physiologically active plasma powder 840 and/orthe reconstitution fluid 850 are connected to the spray dried plasmareconstitution device 860 via a permanent and/or a reusable connection(e.g., syringe connection, standard medical connection, a luer taperconnection, twist and lock connection, one time use connection, etc.).

In other embodiments, the mixer device 862 transfers the reconstitutionfluid 850 into the bag with the physiologically active plasma powder840. The bag with the physiologically active plasma powder 840 can belarge enough to include both the physiologically active plasma powder840 and the reconstitution fluid 850. In a further embodiment, the spraydried plasma reconstitution device can be a syringe with a nozzle (orother fluid input device) that injects the reconstitution fluid into thebag with the physiologically active plasma powder 840. In thisembodiment, the bag with the physiologically active plasma powder 840and the reconstitution fluid 850 can be rocked (manually orautomatically), e.g., for thirty seconds to two minutes to mix thepowder 840 and the fluid 850 together to form the physiologically activereconstituted plasma 890. As shown in FIG. 8B, a dry plasma powderstorage 890 bag may be provided which includes standard input and outputconnectors 891 and 892 to facilitate introduction of reconstitutionfluid, and output of reconstituted plasma e.g., to a standardtransfusion set.

FIG. 9A is a diagram of an exemplary integrated storage andreconstitution device 900. The device 900 includes a spray dried plasmastorage device 950, a spray dried plasma reconstitution device 960, asealing mechanism 955, and a reconstitution device 957. The spray driedplasma storage device 950 includes physiologically active plasma powder952. The dried plasma reconstitution device 960 includes reconstitutionfluid 965.

The sealing mechanism 955 (e.g., plastic seal, ceramic seal, polymerseal, inter lockable connections, etc.) separates the physiologicallyactive plasma powder 952 and the reconstitution fluid 965 from mixingbefore the user and/or the automated control system needs the componentsmixed. The user and/or the automated control system releases the sealingmechanism 955 to release the physiologically active plasma powder 952and the reconstitution fluid 965 to the reconstitution device 957. Thereconstitution device 957 reconstitutes physiologically activereconstituted plasma 990 from the physiologically active plasma powder952 and the reconstitution fluid 965.

In some embodiments, e.g., as shown in FIG. 9B the integrated storageand reconstitution device 900 is a flexible, plastic container and thephysiologically active plasma powder 952 and the reconstitution fluid965 are each stored in a sub compartment of the plastic container. Inthis embodiment, the sealing mechanism 955 forms a seal between the twosub compartments. Upon release of the sealing mechanism 955, thephysiologically active plasma powder 952 and the reconstitution fluid965 mix together. In some embodiments, the reconstitution device 957includes fins within the integrated storage and reconstitution device900 that mix the physiologically active plasma powder 952 and thereconstitution fluid 965 together upon movement of the device 900 (e.g.,shaking by the user, centrifuge by the automated control system, etc.).

FIG. 10 is a flowchart 1000 depicting an exemplary spray drying processfor plasma. A user and/or an automated control system warms up (1005)the spray drying apparatus 240 of FIG. 2 (e.g., pre heats the airstream, pressurizes the apparatus via the vacuum device or pump, etc.).The user and/or the automated control system starts (1010) the spraydrying apparatus 240. The plasma 210 is provided (1020) to the spraydrying apparatus 240. The user and/or the automated control system sets(1030) one or more parameters of the spray drying apparatus 240 (e.g.,inlet temperature, outlet temperature, etc.). The user and/or theautomated control system starts (1040) the spray drying process. Theuser and/or the automated control system collects (1050) thephysiologically active plasma powder 290 from the spray drying apparatus240.

FIG. 11 is a flowchart 1100 depicting another exemplary spray dryingprocess for plasma. A user and/or an automated control system attaches(1110) the dehumidifier 344 to the spray drying apparatus 340 of FIG. 3.The user and/or the automated control system attaches (1115) a pre dryerto the spray drying apparatus 340, e.g., to pre heat air input to heatedair supply 344 (e.g., using hot air output from a dehumidifier or othercomponent of the system). For spray drying systems which do not use preheating, this step may be omitted.

The user and/or the automated control system attaches (1120) glassware(e.g., the drying chamber 352, the cyclone chamber 356, the powdercollection chamber 358, etc.) to the spray drying apparatus 340.Alternatively, as described in reference to FIGS. 13A-13E, a disposableattachment may be used.

The user and/or the automated control system sets (1125) the inlettemperature to a desired value on the spray drying apparatus 340. Theinlet temperature can be, for example, the temperature of the air streamentering the nozzle 348. In other embodiments, the inlet temperature isthe temperature of the atomized plasma as it enters the drying chamber350. In some embodiments the inlet temperature is set to about 112° C.In various embodiments, any suitable inlet temperature may be used,e.g., an inlet temperature in the range of 85-150° C., or in the rangeof 100-120° C., or in the range of 110-115° C., etc.

The user and/or the automated control system sets (1130) the pump ratefor the peristaltic pump 342 to a desired value. In some embodiments thepump rate is set to about 9 mL/minute. In various embodiments, anysuitable pump rate may be used, e.g., a pump rate in the range of 3-14mL/minute, or in the range of 7-11 mL/minute, or in the range of 8-10mL/minute, etc.

The user and/or the automated control system sets (1135) the aspirationof the vacuum supply or drying gas pump to provide a flow rate out ofthe collection device 358 to 35 m³/hour. In various embodiments, anysuitable flow rate may be used, e.g., a flow rate in the range of 25-80m³/hour, or in the range of 30-40 m³/hour, or in the range of 33-37m³/hour, etc.

The user and/or the automated control system sets (1140) the flow ratefrom the non reactive spray gas supply 346 to a desired value, e.g., 414L/hour. In various embodiments, any suitable flow rate may be used,e.g., a flow rate in the range of 300-500 L/hour, or in the range of350-450 L/hour, or in the range of 375-425 L/hour, etc.

The user and/or the automated control system starts (1145) the spraydrying process on the spray drying apparatus 340. The user and/or theautomated control system collects (1160) the physiologically activeplasma powder 390.

During the processing of the plasma 310 by the spray drying apparatus340, an output optimization device (e.g., 261 of FIG. 2) monitors (1150)the outlet temperature of the physiologically active plasma powder 390at the powder collection chamber 358 (or other suitable position) viathe outlet temperature device 354. If the outlet temperature issubstantially outside of the range of 40° C. to 44° C., the outputoptimization device adjusts (1155) the pump rate and/or the inlettemperature to correct the output temperature. Table 1 illustratesexemplary output temperatures and adjustments to the pump rate and/orthe inlet temperature.

TABLE 1 Exemplary Outlet Temperatures and Respective Adjustments. PumpRate Inlet Outlet Set Pump Rate Adjustment Set Inlet TemperatureTemperature (mL/min) (mL/min) Temperature Adjustment 38° C. 11.5 −2 107°C. — 39° C. 11.5 — 107° C. +4° C. 48° C. 11.5 +1 107° C. −1° C. 45° C.11.5 — 107° C. −2° C.

In general, in various embodiments, the spray drying systems describedherein may feature open or closed loop control of one or more processparameters. One or more sensors (e.g., temperature sensors, flow ratesensors, pressure sensors, etc.) may be used to monitor the process.Information from these sensors (either alone or in combination) can beprocessed and used to control one or more process parameter (e.g.,plasma flow rate, drying gas flow rate, spray gas flow rate, drying gasinlet temperature, etc.). For example, a closed servo loop may be usedto control one or more sensed process parameters (e.g., drying gasoutlet temperature, plasma flow rate, drying gas flow rate, spray gasflow rate, drying gas inlet temperature, etc.) at a desired value orrange of values by adjusting one or more other process parameters.Process control may be implemented using any techniques known in theart, e.g., in software (e.g., run on a general purpose computer),hardware, or a combination thereof. For example, various embodimentsfeature closed servo loop control of the spray drying outlet temperatureat a desired value (e.g., 42° C.) or range of values (e.g., 41-43° C.,less than 43° C., etc.) by adjusting, e.g., the plasma pump rate, thedrying gas inlet temperature, or a combination thereof. The servo loopmay be implemented using any techniques know in the art, e.g., insoftware (e.g., run on a general purpose computer), hardware, or acombination thereof.

FIG. 12 is a flowchart 1200 depicting an exemplary process of applyingphysiologically active reconstituted plasma to a human patient utilizingthe integrated storage and reconstitution device 900 of FIG. 9. Theintegrated storage and reconstitution device 900 provides (1210) thephysiologically active plasma powder 952. The integrated storage andreconstitution device 900 provides (1220) the reconstitution fluid 965.The sealing mechanism 955 supplies (1230) the physiologically activeplasma powder 952 and the reconstitution fluid 965 to the reconstitutiondevice 957. The reconstitution device 957 mixes (1240) thephysiologically active plasma powder 952 and the reconstitution fluid965 to form the physiologically active reconstituted plasma 990. A userand/or an automated control system applies (1250) the physiologicallyactive reconstituted plasma 990 to a human patient (e.g., the user, amedical user, etc.).

In some embodiments, the plasma described herein is human plasma. Theplasma can be, for example, diluted (e.g., glycine, water, bloodthinner, etc.) and/or undiluted (e.g., undiluted plasma separated fromthe blood).

In other embodiments, the parameters utilized for the spray dryingapparatus are illustrated in Table 2.

TABLE 2 Parameters for Spray drying Apparatus Parameter Setting Range ARange B Inlet Temperature 107° C. 100° C. to 114° C. 102° C. to 112° C.Pump Setting (mL/min) 11.5  7.1 to 14.4  9.5 to 12.0 Aspiration (m³/hr)35 20 to 35 30 to 35 Spray Flow Rate 414 360 to 475 340 to 445(Nitrogen) (L/hr) Outlet Temperature NA 40° C. to 44° C. 42° C. to 43°C. (Monitor)

In other embodiments, the parameters utilized for the spray dryingapparatus can be varied as illustrated in Table 3.

TABLE 3 Parameters for Spray drying Apparatus Parameter Settings ASettings B Settings C Inlet Temperature 101-113° C.  96-118° C.  85-129° C. Pump Setting (mL/min)  9.8-12.0  9.0-13.0 18.0-15.0Aspiration (m³/hr)  30-35  28-35   20-35 Spray Flow Rate (Nitrogen)390-445 365-450  325-500 (L/hr) Outlet Temperature (Monitor)  38-46° C. 36-48.4° C.   32-61.6° C.

In some embodiments, (e.g., using diluted plasma) the parametersutilized for the spray drying apparatus are dependent on the proteinconcentration of the plasma. In other words, the parameters change basedon the amount of protein per volume of the plasma. For example, in someembodiments, at 10 mg of protein per 100 ml of volume, the inlettemperature setting is 107° C. As another example, in some embodiments,at 25 mg of protein per 100 ml of volume, the inlet temperature settingis 109° C.

In some embodiments, the plasma 310 is cooled (or heated) before beingpumped into the spray drying apparatus 340 by the peristaltic feed pump342. In this example, the bag of plasma can be cooled before beingconnected to the spray drying apparatus 340.

In other embodiments, the human plasma is collected by apheresis. Thehuman plasma can be dried and tested using the spray dry methoddescribed herein.

In some examples, the spray drying apparatus is setup per the parametersand/or steps described below. Although the following steps are numberedsequentially, the steps can occur in any order. The Buchi equipmentand/or parts described herein are available from BÜCHI Labortechnik AGof Flawil, Switzerland.

-   -   1. Provide 200 ml frozen bag of plasma collected by apheresis    -   2. Thaw the frozen bag of plasma in a 38° C. water bath    -   3. Provide the Buchi B 290 spray dryer    -   4. Attach the Buchi B 296 dehumidifier to the spray dryer, for        example, according to Buchi instructions    -   5. Attach Buchi pre dryer heat exchanger to the spray dryer, for        example, according to Buchi instructions    -   6. Attach Buchi outlet HEPA filter to the spray dryer    -   7. Check that all glassware components are clean and dry    -   8. Attach Buchi high volume glassware set to the spray dryer        according to Buchi instructions    -   9. Empty receiving bottle of Buchi B 296 dehumidifier    -   10. Attach thawed bag of plasma to the Buchi B 290 spray dryer    -   11. Set inlet temperature range of spray dryer to 107° C.    -   12. Set pump setting to 11.5 mL/minute (in other examples, the        pump setting is set in a range from 7.1 to 14.4 mL/minute)    -   13. Set aspiration to 35 m³/hr    -   14. Set non reactive gas (e.g., nitrogen) flow rate to 360-475        L/hour depending on flow rate    -   15. Monitor outlet temperature and adjust pump rate (e.g., first        adjustment) and inlet temperature (e.g., second adjustment) to        keep the outlet temperature between 40-44° C.

Plasma spray drying systems of the type described herein provide forclosed sterile processing of plasma into a dried plasma product. Forexample, referring to FIG. 16A, in some embodiments, the spray dryingsystem 1601 receives a single unit of plasma 1602. The plasma isprocessed under closed sterile conditions to produce a single unit ofdried plasma in a closed sterile container 1603. The closed sterilecontainer 1603 may be sealed and removed for closed sterile storage.Such processing may be referred to as unit to unit processing.

Referring to FIG. 16B, in some embodiments, the spray drying system 1601receives plasma from a pool of plasma 1604 (e.g., collected frommultiple donors). The plasma is processed under closed sterileconditions to produce one or more single units of dried plasma, each ina closed sterile container 1605. For example, plasma from the pool 1604may be processed until a first unit of dried plasma is produced andstored in a single storage container 1605. The storage container 1605can then be sealed and removed from the spray dry system 1601 for closedsterile storage. A new empty sterile storage bag 1605 is attached to thespray dry 1601 system without compromising the closed environment of thesystem, and the process is repeated. Such processing may be referred toas pool to unit processing.

Referring to FIG. 16C, in some embodiments, the spray drying system 1601receives multiple single units of plasma 1606 (e.g., collected frommultiple donors) either in sequence or in parallel. The plasma isprocessed under closed sterile conditions to produce a pool of multipleunits of dried plasma in a single closed sterile storage container 1607.For example, a first unit of plasma 1606 may be attached to the spraydrying system without compromising the closed sterile environment of thespray dry system 1601. The unit 1606 is processed, and dried plasmapowder collected in the storage container 1607. Once processing of thefirst unit 1606 is complete, the unit 1606 and/or the storage container1607 is removed without compromising the closed sterile environment ofthe spray dry system 1601. A new unit of plasma 1606 is attached to thespray drying system 1601 while maintaining the closed sterileenvironment of the system, and the process repeated. Once spray driedplasma powder from several plasma units 1606 has been collected in thestorage container 1607, the storage container 1607 is sealed and removedfor closed sterile storage. Such processing may be referred to as poolto unit processing.

Referring to FIG. 16D, in some embodiments, the spray drying system 1601receives plasma from a pool of plasma 1608 (e.g., collected frommultiple donors). The plasma is processed under closed sterileconditions to produce a pool of multiple units of dried plasma in asingle closed sterile storage container 1609. For example, a volume ofplasma equivalent to multiple units is delivered from the pool 1608 forprocessed under closed sterile conditions. The resulting dried plasmapowder is stored in a single storage container 1605. After a desiredamount of powder is collected, the storage container 1609 can then besealed and removed from the spray dry system 1601 for closed sterilestorage. Such processing may be referred to as pool to pool processing.

In various embodiments, a single spray drying system may operate inmultiple modes corresponding to some or all of the above describedprocessing schemes (unit to unit, pool to unit, unit to pool, pool topool, etc.). Advantageously, such systems may switch between modeswithout requiring substantial reconfiguration of the system.

Example I

Table 4 illustrates test results between fresh frozen plasma, spraydried plasma rehydrated with 2 mL of water, and spray dried plasmapowder rehydrated with 2 mL of glycine. The text results were obtainedusing a STart® 4 semi automated homeostasis analyzer available fromDiagnostica Stago, Inc. of Parsippany, N.J. Note that the Factor V andFactor VII values of the FFP are presented as a clotting time value withunits of seconds, and not as an absolute level in units of IU/dL.

TABLE 4 Spray dried Plasma vs. Fresh Frozen Plasma Total Percentage ofProtein Prothrombin Factor Factor Protein Compared to Fresh Time (PT) VVII (mg/mL) Frozen Plasma (sec) (sec) (sec) Fresh Frozen Plasma 50 NA 1515 16 Spray Dried Plasma rehydrated with 2 mL water 100 mg 31  61% 18 1816 200 mg 56 111% 16 16 16 300 mg 78 155% 19 20 19 Spray Dried Plasmarehydrated with 2 mL glycine 100 mg 35  69% 18 16 16 200 mg 61 121% 1515 16 300 mg 82 163% 16 16 16 400 mg 97 193% 18 17 17

Example II

FIG. 17A shows a chart which illustrates the results of tests on spraydried plasma samples. Fresh plasma (<24 hour from draw) was dried undervarying processing conditions. A first set of dried plasma units wasdried with an inlet temperature of 97° C. and a fixed plasma flow rateof 3 mL/min. A second set was dried with a drying gas inlet temperatureof 97° C. and with a plasma flow rate which was varied to maintain adesired gas outlet temperature. A third set was dried with a drying gasinlet temperature of 112° C. and with a plasma flow rate which wasvaried to maintain a desired gas outlet temperature. A fourth set wasdried with a drying gas inlet temperature of 117° C. and with a plasmaflow rate which was varied to maintain a desired gas outlet temperature.

A sample from each of the dried units was reconstituted in deionizedwater (e.g., at a ratio of 0.09 g of powder per mL of deionized water).The reconstituted plasma was tested with a Stago Compact series analyzeravailable from available from Diagnostica Stago, Inc. of Parsippany,N.J. The samples were tested for PT, aPTT, Fibrinogen Level, levels ofFactors V, VII, VIII, and IX, Protein C level, and Protein S level. Theresults are presented in FIG. 17A.

FIG. 17B shows a chart which illustrates the results of tests on spraydried plasma samples. Fresh plasma (<24 hour from draw) was dried undervarying processing conditions. The samples were run at various inlettemperatures ranging from 97-112° C. (batches labeled 2010-102 and2010-104 at 97° C.; batches labeled 2010-040 through 2010-074 at 112°C., and batches labeled 2010-081 and 2010-083 at 117° C.). In each case,the plasma flow was varied to maintain a desired gas outlet temperature.

Each sample was reconstituted using a glycine solution (e.g., at a ratioof 0.09 g of powder per mL of reconstitution fluid). The reconstitutedplasma was tested with a Stago STA series analyzer available fromavailable from Diagnostica Stago, Inc. of Parsippany, N.J. The sampleswere tested for PT, aPTT, Fibrinogen Level, levels of Factors V, VII,VIII, and IX, Protein C level, and Protein S level. The results arepresented in FIG. 17B.

DEFINITIONS

aPTT—Activated Partial Thromboplastin Time is a performance indicatorknown in the art measuring the efficacy of both the “intrinsic”(sometimes referred to as the contact activation pathway) and the commoncoagulation pathways.

PT—Prothrombin Time is a performance indicator known in the art of theextrinsic pathway of coagulation.

FGN—Fibrinogen (also referred to in the art as Factor I) is an a solubleplasma glycoprotein, synthesized by the liver, that is converted bythrombin into fibrin during coagulation.

PC—Protein C is also known as autoprothrombin HA and blood coagulationFactor XIV, is an inactive protein, the activated form of which plays animportant role in managing blood clotting, inflammation, cell death andthe permeability of blood vessel walls in humans and other animals.

PS—Protein S is a vitamin K-dependent plasma glycoprotein synthesized inthe endothelium. In the circulation, Protein S exists in two forms: afree form and a complex form bound to complement protein C4b. In humans,protein S is encoded by the PROS1 gene. The best characterized functionof Protein S is its role in the anti coagulation pathway, where itfunctions as a cofactor to Protein C in the inactivation of Factors Vaand VIIIa. Only the free form has cofactor activity.

Factors—As used here a “Factor” followed by a Roman Numeral refers to aseries of plasma proteins which are related through a complex cascade ofenzyme-catalyzed reactions involving the sequential cleavage of largeprotein molecules to produce peptides, each of which converts aninactive zymogen precursor into an active enzyme leading to theformation of a fibrin clot. They include: Factor I (fibrinogen), FactorII (prothrombin), Factor III (tissue thromboplastin), Factor IV(calcium), Factor V (proaccelerin), Factor VI (no longer consideredactive in hemostasis), Factor VII (proconvertin), Factor VIII(antihemophilic factor), Factor IX (plasma thromboplastin component;Christmas factor), Factor X (Stuart factor), Factor XI (plasmathromboplastin antecedent), Factor XII (hageman factor), and Factor XIII(fibrin stabilizing factor).

Although the methods and apparatuses described herein are described asprocessing/utilizing plasma, the method and apparatuses described hereincan, for example, be utilized to process/utilize any type of bloodproduct (e.g., whole blood, blood platelets, red blood cells, bloodserum, etc.).

Comprise, include, and/or plural forms of each are open ended andinclude the listed parts and can include additional parts that are notlisted. And/or is open ended and includes one or more of the listedparts and combinations of the listed parts.

One or more documents are incorporated by reference in the currentapplication. In the event that the meaning of a technical term in anincorporated document conflicts with the current application, themeaning in the current application is controlling.

One skilled in the art will realize the invention may be embodied inother specific forms without departing from the spirit or essentialcharacteristics thereof. The foregoing embodiments are therefore to beconsidered in all respects illustrative rather than limiting of theinvention described herein. Scope of the invention is thus indicated bythe appended claims, rather than by the foregoing description, and allchanges that come within the meaning and range of equivalency of theclaims are therefore intended to be embraced therein.

What is claimed is:
 1. A system for spray drying pooled plasma,comprising: a plasma collection device and pooling the collected plasma;at least one of a fluid processing and washing device, an ultravioletdevice, or a fluid filter for cleaning the pooled plasma; and a spraydrying apparatus for drying the cleaned pooled plasma, including anattachment, comprising: a plasma inlet port for providing sterilecommunication to a plasma source; a spray gas inlet port for providingremovable sterile communication to a pressurized gas source; at leastone drying gas inlet port for providing removable sterile communicationto a drying gas source; a spray dry nozzle in fluid communication withthe plasma and spray gas inlets; a drying chamber in fluid communicationwith the attached spray nozzle and drying gas inlet to receive a sprayof plasma for drying; a particle collection device configured to collectspray dried plasma from an outlet of the drying chamber; and acollection device gas outlet port in sterile fluid communication withthe particle collection device; wherein the spray nozzle, dryingchamber, and collection device define a sterile isolated interiorvolume.